Experience in treatment of patients with arterial and venous thrombosis with proven COVID-19
https://doi.org/10.17802/2306-1278-2021-10-4-131-141
Abstract
Background. COVID-19 is represented by a large number of different phenotypes, ranging from asymptomatic progress to the development of severe multiple organ dysfunction syndrome. The mechanisms of development of multiple organ dysfunction syndrome are multifactorial, including hypercoagulation with the formation of blood clots. They are often diagnosed as thrombotic complications with detection of blood clots not only in the veins and pulmonary arteries, but also in the heart and main arteries. An observational study shows that the incidence of venous and arterial thrombosis is as high as 31% in patients with COVID-19 pneumonia. However, large studies have not yet been conducted.
Aim. To generalize and analyze our own observations of the clinical course of patients with thrombosis and COVID-19.
Methods. The study included 5 male patients who had arterial and venous thrombosis and COVID-19 positive test. Results The experience of treatment of 5 patients with COVID-19 with arterial and venous thrombosis was analyzed. All patients showed characteristic changes in the coagulogram. The patient who, upon admission, had a negative test for COVID-19, and characteristic changes in the coagulogram appeared on the day of recurrent thrombosis, was of greatest interest. All patients received standard treatment and were discharged with improvement after testing negative for COVID-19.
Conclusion. Generalization of the clinical course of patients with COVID-19 and thrombosis of various vascular regions allowed us to develop treatment tactics for these groups of patients.
About the Authors
E. M. Shpilyanskiy
State Budgetary Healthcare Institution “Korolev City Hospital”;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)
Russian Federation
Russian Federation
Shpilyanskiy Eduard M., PhD, MD, Chief Physician of the State Budgetary Healthcare Institution “Korolev City Hospital”, Korolev, Russian Federation; Professor at the Department of Public Health and Healthcare named after N.A. Semashko of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)
24, Tsiolkovsky St., Korolev, Moscow region, 141070,
8-2, Trubetskaya St., Moscow, 119991
E. V. Roitman
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Roitman Evgeny V., Doctor of Biological Sciences, Professor of the Department of Oncology, Hematology and Radiation Therapy of the Pediatric Faculty
1, Ostrovityanova St. Moscow, 117997
K. M. Morozov
Center of Medicine and Rehabilitation (Premium Clinic)
Russian Federation
Russian Federation
Morozov Konstantin M., MD, Cardiovascular Surgeon
6a, Yubileyniy Ave., Khimki, 141407
T. V. Sukhareva
State Budgetary Healthcare Institution “Korolev City Hospital”
Russian Federation
Russian Federation
Sukhareva Tatiana V., PhD, Cardiovascular Surgeon of the Surgical Department No. 1
24, Tsiolkovsky St., Korolev, Moscow region, 141070
References
1. Lok FA Kruip Mjha, van der Meer Njm et al. – Trombosis reserch 2020, HTTPS://DOI.ORG/10.1016/ J. Tromres 2020.04.013
2. https://www.nejm.org/doi/full/10.1056/NEJMc2007575
3. https://www.krasotaimedicina.ru/diseases/rheumatology/antiphospholipid-syndrome
4. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020. doi:10.1111/jth.14768
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054- 1062. doi:10.1016/S0140-6736(20)30566-3
6. Mycroft-West CJ, Su D, Elli S, et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. bioRxiv. 2020:2020.02.29.971093. doi:10.1101/2020.02.29.971093
7. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020. doi:10.1111/jth.14810
8. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766543
9. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. doi:10.1111/jth.14817
10. Li J, Li Y, Yang B, Wang H, Li L. Low-molecularweight heparin treatment for acute lung injury/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2018;11(2):414-422.
11. Кубанов А.А., Дерябин Д.Г. Вестник Российской академиимедицинский наук Новый взгляд на патогенез COVID-19: заболевание является генерализованным вирусным васкулитом, а возникающее при этом поражение легочной ткани ― вариантом ангиогенного отека легкого Вестник Российской академиимедицинский наук Том 75, № 2 (2020)
12. http://eclinpath.com/hemostasis/tests/screening-coagulationassays/; The 5-Minute Veterinary Consult: Blackwell's Five-Minute Veterinary Consult: Canine and Feline by Lawrence P. Tilley, Francis W. K. Smith and Larry P. Tilley, 2008.
13. https://icvtormet.ru/krov/4-gruppa-koronavirus .
14. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up, Journal of the American College of Cardiology (2020), doi: https://doi.org/10.1016/j.jacc.2020.04.031.
15. ACC/Chinese Cardiovascular Association COVID-19 Webinar 1. https://www.youtube.com///
16. https://static-1.rosminzdrav.ru/system/attachments/attaches/000/049/951/original/09042020COVID-19_v5.pdf.
17. Hunt B et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. March 25, 2020. Published on.
Review
For citations:
Shpilyanskiy E.M., Roitman E.V., Morozov K.M., Sukhareva T.V. Experience in treatment of patients with arterial and venous thrombosis with proven COVID-19. Complex Issues of Cardiovascular Diseases. 2021;10(4):131-141. (In Russ.) https://doi.org/10.17802/2306-1278-2021-10-4-131-141
Views:
389
